Lactic Acid

Evidence Level: L5

Predicted Indications: 5

Lactic Acid

Pharmacist Assessment Report

Lactic Acid: From an Unspecified Approved Indication to Atypical Coarctation of Aorta

One-Sentence Summary

Lactic acid is marketed in Canada in three products (PRISMASOL and PRISMOCAL solutions), but the compiled data do not state an approved indication for them. The TxGNN model predicts it may be effective for atypical coarctation of aorta, with a very high score but no clinical trials and no directly relevant publications supporting this direction. The evidence is model prediction only. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Quick Overview

Item	Content
Original Indication	Not specified in the data compiled for this report
Predicted New Indication	Atypical coarctation of aorta
TxGNN Prediction Score	0.9959
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Lactic acid is a naturally occurring metabolite. In Canada it is marketed in three products with the brand names PRISMOCAL and PRISMASOL, but the data compiled for this report do not describe their approved use.

On the biology, a plausible link to the predicted indication is hard to find. Atypical coarctation of the aorta is a structural congenital anomaly managed surgically or by catheter intervention. Lactic acid has no recognised mechanism that would correct such a defect. The very high TxGNN score (0.9959) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The prediction should be treated as a hypothesis-generating signal at best.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the top-ranked indication.

The second-ranked prediction, aortic malformation (score 0.9935), returned 14 publications. None tests lactic acid as a therapy. They are perioperative lactate-biomarker studies in paediatric cardiac surgery, biodegradable device and stent studies, and an animal study of aortic wall metabolism. They offer no support for a therapeutic role.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02274876	PRISM0CAL	Not stated	Not stated
02243095	PRISMASOL 0	Not stated	Not stated
02277476	PRISMASOL 4	Not stated	Not stated

Safety Considerations

Drug Interactions: 17 interactions were identified, all graded Moderate or Minor.
- Moderate (10): doxycycline, tetracycline, minocycline, demeclocycline, oxytetracycline, acetylsalicylic acid, sodium salicylate, ephedrine (including nasal), and pseudoephedrine.
- Minor (7): sulfonylureas (chlorpropamide, tolazamide, glipizide, glyburide, acetohexamide, tolbutamide) and methotrexate.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone, with no trials, no relevant literature, and no plausible mechanism linking lactic acid to a structural aortic anomaly. The other nine top-ranked predictions are also L5 and also rated Hold. Several are structural congenital defects with no plausible mechanism.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications, which are currently missing and block safety screening
Mechanism of action data for lactic acid
The approved indications and dosage forms for the three Canadian products
Any direct preclinical or clinical evidence that lactic acid affects the predicted disease. Without it, resources are better spent on other candidates.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.